Targeted contrast agents to better detect pancreatic tunor and its zinc content by MRI on mice

Projektinformationen

tZR-CA-InVivo

ID Finanzhilfevereinbarung: 898850

DOI 10.3030/898850

EK-Unterschriftsdatum 10 April 2020

Startdatum 1 November 2021

Enddatum 3 Mai 2026

Finanziert unter

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Gesamtkosten € 196 707,84

EU-Beitrag € 196 707,84

Koordiniert durch

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
France

Projektbeschreibung

Bestimmung der Zinkkonzentration in Tumoren mittels Magnetresonanztomografie

Da die Schnelldiagnose und Heilung von Bauchspeicheldrüsenkrebs schwierig ist, sind die Prognosen schlecht und die Überlebensraten niedrig. Neuere Erkenntnisse legen nahe, dass Pankreastumorzellen einen geringen Anteil an Zinktransportern und niedrige Zinkkonzentrationen aufweisen und eine Therapie mit dem Zinkionophor Clioquinol das Tumorwachstum hemmen. Das EU-finanzierte Projekt tZR-CA-InVivo entwickelt ein zinkresponsives Kontrastmittel für die Magnetresonanztomografie, mit dem sich der Zinkgehalt in Geweben quantifizieren lässt. Da das Kontrastmittel spezifisch auf den Tumor ausgerichtet ist, kann so die Zinkkonzentration bei den Betroffenen überwacht und bei Bedarf eine Höherdosierung veranlasst werden.

Ziel

Pancreatic cancer has the lowest survival rate Pancreatic cancer has the lowest survival rate of all cancers in Europe, the median survival time is only a few months due to the lack of test for early diagnosis, and no effective therapies for metastatic forms. Pancreatic Ductal Adenocarcinoma (PDAC), like prostate and hepatocellular cancers present a down regulation of zinc importers and low zinc content. Treatment with clioquinol, a zinc ionophore, to increase the amount of zinc in the tumor has shown to inhibit tumor growth.

This project aims at creating new tool to better detect PDAC by Magnetic Resonance Imaging, and the evaluation of di zinc ionophore to elevate the content in zinc in the tumor environment.

Using the same modular approach, a normal and a zinc responsive contrast agent targeted to the PDAC will be synthesized by conjugation of a peptidic sequence known to target the tumor bearing a Single Core Multimodal Imaging Platform for quantification, with a peptide functionalized with a normal or zinc responsive contrast agent. After careful characterizations in vitro and ex vivo, they will be used in mice implanted with orthoptic pancreatic tumors.

One of the projects developed by the “Metallic complexes for MRI” group, consist designing and using MRI probe for various substrates, including zinc. The group masters all the techniques to characterize the contrast agents, and the experience researcher (ER) will bring the knowledge about zinc biology, and infrared microscopy to quantify the contrast agent in tissues.

Benefiting from the competitive interdisciplinary environment of CBM, and within the group, the ER will acquire new technical skills, knowledge and network the frontier between chemistry, biology and MRI imaging, in particular working with animal model (mice), to adequately implement the project and complete her skill set to become an independent researcher interested in developing tools to study the role of metals in biological context.

Wissenschaftliches Gebiet

• medical and health sciences › clinical medicine › oncology › prostate cancer
• natural sciences › chemical sciences › inorganic chemistry › transition metals
• natural sciences › biological sciences › biochemistry › biomolecules
• engineering and technology › medical engineering › diagnostic imaging › magnetic resonance imaging
• medical and health sciences › clinical medicine › oncology › pancreatic cancer

Schlüsselbegriffe

• MRI zinc responsive probe
• Peptide
• PDAC

Programm/Programme

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Thema/Themen

• MSCA-IF-2019 - Individual Fellowships

Aufforderung zur Vorschlagseinreichung

H2020-MSCA-IF-2019

Finanzierungsplan

MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)

Koordinator

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

• Netto-EU-Beitrag: € 196 707,84
• Adresse: RUE MICHEL ANGE 3 ; 75794 Paris ; Frankreich
• Region: Ile-de-France › Ile-de-France › Paris
• Aktivitätstyp: Research Organisations
• Gesamtkosten: € 196 707,84